Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 2Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Multiple Myeloma 27Breast Neoplasms 23Neoplasms 22Pancreatic Neoplasms 19Prostatic Neoplasms 17Glioma 17Glioblastoma 16Leukemia, Myeloid, Acute 15Recurrence 14Solid Tumor 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Hematologic Neoplasms 8Melanoma 7Lymphoma, B-Cell 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Polycystic Ovary Syndrome 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Myelodysplastic Syndromes 5Leukemia, Plasma Cell 5

Interventions

Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Retinoblastoma × Clear all
NCT06424301 2025-06-26

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

Eye & ENT Hospital of Fudan University

Phase EARLY_PHASE1 Recruiting
2 enrolled
Other solid neoplasm

Retinoblastoma

NCT06972602 2025-05-15

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Eye & ENT Hospital of Fudan University

Phase EARLY_PHASE1 Recruiting
10 enrolled
Other solid neoplasm

Recurrence, Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡